Paper36726985
The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes.
Wang M and 3 others. Front Immunol, 2022. Cited by 31 papers, by iCite.
Cite this record
ConductScience Library. The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes. Papers, record 36726985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36726985
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gastrointestinal Microbiome | Major topic |
| Neoplasms | Major topic |
| Tumor Microenvironment | Major topic |
| Humans | |
| Immune System | |
| Treatment Outcome | |
| Dysbiosis |
Source PubMed
References170
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19448631 | A protective function for interleukin 17A in T cell-mediated intestinal inflammation. | Nat Immunol | 2009 | https://conductscience.org/library/papers/19448631 | PubMed |
| 2 | 23664135 | Cell type-specific function of TAK1 in innate immune signaling. | Trends Immunol | 2013 | https://conductscience.org/library/papers/23664135 | PubMed |
| 3 | 28314212 | Gene delivery of TIPE2 inhibits breast cancer development and metastasis via CD8+ T and NK cell-mediated antitumor responses. | Mol Immunol | 2017 | https://conductscience.org/library/papers/28314212 | PubMed |
| 4 | 30030152 | Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus. | J Invest Dermatol | 2019 | https://conductscience.org/library/papers/30030152 | PubMed |
| 5 | 7518614 | Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. | Science | 1994 | https://conductscience.org/library/papers/7518614 | PubMed |
| 6 | 20203013 | Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. | Science | 2010 | https://conductscience.org/library/papers/20203013 | PubMed |
| 7 | 30450098 | Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation. | Front Immunol | 2018 | https://conductscience.org/library/papers/30450098 | PubMed |
| 8 | 33303685 | Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. | Science | 2021 | https://conductscience.org/library/papers/33303685 | PubMed |
| 9 | 35262957 | Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC. | Hepatology | 2023 | https://conductscience.org/library/papers/35262957 | PubMed |
| 10 | 29107330 | Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. | Cell | 2017 | https://conductscience.org/library/papers/29107330 | PubMed |
| 11 | 30940817 | Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice. | Nat Commun | 2019 | https://conductscience.org/library/papers/30940817 | PubMed |
| 12 | 30809227 | Germ-Free Mice Exhibit Mast Cells With Impaired Functionality and Gut Homing and Do Not Develop Food Allergy. | Front Immunol | 2019 | https://conductscience.org/library/papers/30809227 | PubMed |
| 13 | 30521105 | A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. | Cancer | 2019 | https://conductscience.org/library/papers/30521105 | PubMed |
| 14 | 25216087 | Host adaptive immunity alters gut microbiota. | ISME J | 2015 | https://conductscience.org/library/papers/25216087 | PubMed |
| 15 | 34209703 | Macrophage Polarization States in the Tumor Microenvironment. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34209703 | PubMed |
| 16 | 25818339 | Immune evasion in cancer: Mechanistic basis and therapeutic strategies. | Semin Cancer Biol | 2015 | https://conductscience.org/library/papers/25818339 | PubMed |
| 17 | 29634943 | T Cell Dysfunction in Cancer. | Cancer Cell | 2018 | https://conductscience.org/library/papers/29634943 | PubMed |
| 18 | 27079802 | Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/27079802 | PubMed |
| 19 | 32433595 | Interaction between microbiota and immunity in health and disease. | Cell Res | 2020 | https://conductscience.org/library/papers/32433595 | PubMed |
| 20 | 25545101 | The impact of diet and lifestyle on gut microbiota and human health. | Nutrients | 2014 | https://conductscience.org/library/papers/25545101 | PubMed |
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42655018 | Integrated Metagenomic and Metabolomic Profiling Identifies Severity-Specific Gut Microbiota Signatures Across A-B-E Phenotypes in Clinically Stable COPD: A Cross-Sectional Study. | Microorganisms | 2026 | https://conductscience.org/library/papers/42655018 | PubMed |
| 42581182 | Gut microbiota modulation of systemic immunity and cancer immunotherapy: mechanisms, evidence, and therapeutic implications. | Saudi Pharm J | 2026 | https://conductscience.org/library/papers/42581182 | PubMed |
| 42566149 | Live Biotherapeutic Products (LBPs) as Promising Microbiome-Based Medicines for Colorectal Cancer (CRC): Mechanistic Basis, Therapeutic Applications, and Translational Challenges. | Probiotics Antimicrob Proteins | 2026 | https://conductscience.org/library/papers/42566149 | PubMed |
| 42507333 | Microbiome-guided cancer immunotherapy: immune mechanisms, resistance pathways, and translational opportunities for precision oncology. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42507333 | PubMed |
| 42293411 | Multi-omics reveals circadian regulation of bone homeostasis by gut microbiota metabolites: mechanisms and chronotherapeutic implications. | Front Immunol | 2025 | https://conductscience.org/library/papers/42293411 | PubMed |
| 42278531 | What Does Bacteria Have to Do with Cancer? The Influence of the Body's Microbiota on Cancer in Cats and Dogs. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278531 | PubMed |
| 42201625 | Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization. | Folia Microbiol (Praha) | 2026 | https://conductscience.org/library/papers/42201625 | PubMed |
| 41971324 | Clinical application of fecal microbiota transplantation and its influencing factors. | Front Microbiol | 2026 | https://conductscience.org/library/papers/41971324 | PubMed |
| 41860665 | Exploring the role of metabolic disorders and gut microbiome in immune checkpoint regulation in cancer: PI3K/AKT/mTOR focus. | J Physiol Biochem | 2026 | https://conductscience.org/library/papers/41860665 | PubMed |
| 41695569 | Gut microbiota-immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities. | Oncol Rev | 2025 | https://conductscience.org/library/papers/41695569 | PubMed |
| 41597210 | Microbial Modulation: Unraveling the Influence of Gut Microbiota on Macrophage Polarization in Tumor Microenvironments. | Cells | 2026 | https://conductscience.org/library/papers/41597210 | PubMed |
| 41578124 | Altered abundance in cancer patients gut of diadenylate cyclase-encoding bacteria. | Sci Rep | 2026 | https://conductscience.org/library/papers/41578124 | PubMed |
| 41479870 | Guardians within: Cross-talk between the gut microbiome and host immune system. | World J Gastrointest Pathophysiol | 2025 | https://conductscience.org/library/papers/41479870 | PubMed |
| 41333317 | Understanding microbiota-driven oncogenesis: The role of metabolites in tumorigenesis. | iScience | 2025 | https://conductscience.org/library/papers/41333317 | PubMed |
| 41322357 | Emerging risk factors and the role of gut microbiota in immunomodulation and therapeutic implications in colorectal cancer. | Cancer Pathog Ther | 2026 | https://conductscience.org/library/papers/41322357 | PubMed |
| 40732979 | The Potential of Nutraceutical Supplementation in Counteracting Cancer Development and Progression: A Pathophysiological Perspective. | Nutrients | 2025 | https://conductscience.org/library/papers/40732979 | PubMed |
| 40724502 | Gastric Cancer and Microbiota: Exploring the Microbiome's Role in Carcinogenesis and Treatment Strategies. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40724502 | PubMed |
| 40323477 | The gastrointestinal mycobiome in inflammation and cancer: unraveling fungal dysbiosis, pathogenesis, and therapeutic potential. | Med Oncol | 2025 | https://conductscience.org/library/papers/40323477 | PubMed |
| 40066456 | Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products. | Front Immunol | 2025 | https://conductscience.org/library/papers/40066456 | PubMed |
| 39796717 | Effect of Gut Dysbiosis on Onset of GI Cancers. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39796717 | PubMed |
Genes47
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36726985
GET https://conductscience.org/api/papers/v1/36726985/references?page=2